Similarly, the Ha2bm promoter-regulated oncolytic Ad showed more potent reduction in viability of cancer cells than did the a2bm promoter-driven oncolytic Ads in AFP-positive and -negative HCCs (Fig. 3B). This evidence concerns the gene AFP and cancer.